ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

IMRX Immuneering Corporation

1.58
0.02 (1.28%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Immuneering Corporation IMRX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.02 1.28% 1.58 17:27:20
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.73 1.60 1.73 1.64 1.56
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
09/4/202411:00GLOBEIMM-1-104 is Synergistic with Chemotherapy in Pancreatic..
03/4/202415:05GLOBEImmuneering to Participate in the 23rd Annual Needham..
27/3/202407:00GLOBEImmuneering Announces First Patient Dosed in its Phase 1/2a..
14/3/202406:00GLOBEImmuneering Announces Positive Topline Results from Phase 1..
12/3/202407:00GLOBEImmuneering Appoints Thomas J. Schall, Ph.D. to its Board of..
11/3/202407:00GLOBEImmuneering Doses First Patient in Phase 2a Clinical Trial..
05/3/202416:00GLOBEImmuneering to Present Preclinical Data on Universal-RAS..
04/3/202407:00GLOBEImmuneering to Participate in the Cowen 44th Annual Health..
01/3/202407:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
01/3/202407:00GLOBEImmuneering Reports Fourth Quarter and Full Year 2023..
01/3/202406:58EDGAR2Form 8-K - Current report
20/2/202407:00GLOBEImmuneering Receives FDA Fast Track Designation for..
09/2/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202415:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202415:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202415:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202415:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202415:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:15EDGAR2Form 8-K - Current report
16/1/202415:37EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
02/1/202415:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202307:00GLOBEImmuneering Announces FDA Clearance of IND Application for..
20/11/202315:05GLOBEImmuneering to Present at the 35th Annual Piper Sandler..
09/11/202315:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202315:05GLOBEImmuneering Reports Third Quarter 2023 Financial Results and..
12/10/202315:05GLOBEImmuneering Presents Preclinical Data Demonstrating..
04/10/202315:05GLOBEImmuneering to Present Preclinical Data on IMM-1-104 and..
06/9/202307:00GLOBEImmuneering to Present at the Morgan Stanley Healthcare..
03/8/202315:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202315:05GLOBEImmuneering Reports Second Quarter 2023 Financial Results..
03/8/202315:04EDGAR2Form 8-K - Current report
05/6/202307:00GLOBEImmuneering Completes Dose Escalation in the IMM-1-104 Phase..
30/5/202307:00GLOBEImmuneering to Present at the Jefferies Healthcare..

Su Consulta Reciente

Delayed Upgrade Clock